LEVETIRACETAM tablet, film coated アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

levetiracetam tablet, film coated

bryant ranch prepack - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 500 mg - levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4) ]. there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who are taking levetiracetam during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. ri

LEVETIRACETAM tablet, film coated アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

levetiracetam tablet, film coated

zydus lifesciences limited - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 250 mg - levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam tablets are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam tablets are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. levetiracitam is contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who are taking levetiracetam during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or vi

LEVETIRACETAM ALTAN 100 MGML イスラエル - 英語 - Ministry of Health

levetiracetam altan 100 mgml

propharm ltd - levetiracetam - concentrate for solution for infusion - levetiracetam 100 mg / 1 ml - levetiracetam - levetiracetam altan 100 mg/ml is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.levetiracetam altan 100 mg/ml is indicated as adjunctive therapy•in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents patients and children from 4 years of age with epilepsy.•in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy•in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.levetiracetam altan 100 mg/ml is an alternative for patients when oral administration is temporarily not feasible.

APO-Levetiracetam Oral levetiracetam 100 mg/mL amber glass bottle オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

apo-levetiracetam oral levetiracetam 100 mg/ml amber glass bottle

southern cross pharma pty ltd - levetiracetam, quantity: 100 mg/ml - solution - excipient ingredients: propyl hydroxybenzoate; maltitol; purified water; sodium citrate dihydrate; glycerol; ammonium glycyrrhizinate; methyl hydroxybenzoate; acesulfame potassium; citric acid monohydrate; flavour - apo-levitiracetam oral solution is indicated for:,? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment,of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary,generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12,years of age with juvenile myoclonic epilepsy (jme),,? add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and,children from 4 years of age with idiopathic generalized epilepsy (ige).

LEVETIRACETAM MYLAN アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

levetiracetam mylan

mcdermott laboratories ltd t/a gerard laboratories - levetiracetam - film coated tablet - 1000 milligram - levetiracetam

LEVETIRACETAM MYLAN アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

levetiracetam mylan

mcdermott laboratories ltd t/a gerard laboratories - levetiracetam - film coated tablet - 500 milligram - levetiracetam

LEVETIRACETAM MYLAN アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

levetiracetam mylan

mcdermott laboratories ltd t/a gerard laboratories - levetiracetam - film coated tablet - 250 milligram - levetiracetam

Levetiracetam Hospira 欧州連合 - 英語 - EMA (European Medicines Agency)

levetiracetam hospira

pfizer europe ma eeig - levetiracetam - epilepsy - antiepileptics, - levetiracetam hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.levetiracetam hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.levetiracetam hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.

Levetiracetam Sun 欧州連合 - 英語 - EMA (European Medicines Agency)

levetiracetam sun

sun pharmaceutical industries europe b.v. - levetiracetam - epilepsy - other antiepileptics - levetiracetam sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.levetiracetam sun concentrate is an alternative for patients when oral administration is temporarily not feasible.

LEVETIRACETAM tablet, film coated アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

levetiracetam tablet, film coated

redpharm drug, inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 1000 mg - 1.1 partial onset seizures levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy. 1.2 myoclonic seizures in patients with juvenile myoclonic epilepsy levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. 1.3 primary generalized tonic-clonic seizures levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. none 8.1 pregnancy levetiracetam blood levels may decrease during pregnancy [see warnings and precautions (5.9)]. pregnancy category c there are no adequate and controlled studies in pregnant women. in animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therape